Skip to main content
Terug
ADCT logo

ADC Therapeutics S.A.

Datakwaliteit: 100%
ADCT
NYSE Healthcare Biotechnology
€ 4,05
▲ € 0,19 (4,92%)
Marktkapitalisatie: 514,53M
Dagbereik
€ 3,94 € 4,11
52-Weeksbereik
€ 1,05 € 4,98
Volume
583.128
50D / 200D Gem.
€ 3,98 / € 3,66
Vorige Slotkoers
€ 3,86

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -3,6 0,4
P/B 2,9
ROE % 3,7
Net Margin % -175,3 3,8
Rev Growth 5Y % 24,5 10,0
D/E 0,2

Belangrijkste Punten

Revenue grew 24,45% annually over 5 years — strong growth
Negative free cash flow of -141,44M
PEG of 0,10 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 9,60%
Capital efficient — spends only 0,32% of revenue on capex

Groei

Revenue Growth (5Y)
24,45%
Revenue (1Y)14,85%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-32,11%
Net Margin-175,31%
Op. Margin-133,21%

Veiligheid

Debt / Equity
N/A
Current Ratio4,37
Interest Coverage-2,10

Waardering

P/E Ratio
-3,61
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 14,85% Revenue Growth (3Y) 8,15%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 24,45% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 81,36M Net Income (TTM) -142,62M
ROE N/A ROA -44,14%
Gross Margin 90,57% Operating Margin -133,21%
Net Margin -175,31% Free Cash Flow (TTM) -141,44M
ROIC -32,11% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,37
Interest Coverage -2,10 Dividend Yield 0,00%
Valuation
P/E Ratio -3,61 P/B Ratio N/A
P/S Ratio 6,32 PEG Ratio 0,10
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 514,53M Enterprise Value 692,20M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 81,36M 70,84M 69,56M 209,91M 33,92M
Net Income -142,62M -157,85M -240,05M -157,13M -230,03M
EPS (Diluted) -1,12 -1,62 -2,94 -1,99 -3,00
Gross Profit 73,68M 64,89M 67,03M 206,61M 32,52M
Operating Income -108,38M -130,65M -165,99M -123,34M -261,72M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 323,15M 321,98M 354,78M 490,86M 617,97M
Total Liabilities 508,98M 524,62M 503,03M 411,41M 451,88M
Shareholders' Equity -185,83M -202,64M -148,25M 79,45M 166,09M
Total Debt 439,01M 123,00M 124,38M 129,85M 139,70M
Cash & Equivalents 261,34M 250,87M 278,60M 326,44M 466,54M
Current Assets 306,34M 307,39M 336,29M 434,98M 525,18M
Current Liabilities 70,16M 80,47M 67,67M 81,94M 73,94M